Clinical Guest Contributors
-
Why Pharmas/Biotechs Should Champion Non-Pharmaceutical Interventions For MDR Pathogens
2/5/2024
Multi-drug resistant (MDR) pathogens are an escalating concern. While the primary focus of MDR pathogen treatment strategies has revolved around the creation of innovative therapeutics, diagnostic tools, and antibiotic stewardship, there has been a limited emphasis on implementing non-pharmaceutical interventions (NPIs). Regardless of what indication your drug's clinical trial is investigating, implementing NPIs will actually help your trial be more successful.
-
Incorporating SOGI Data In Clinical Research And Impacts On Enhancing Cancer Treatment Outcomes
2/2/2024
Collecting and measuring SOGI information in cancer care and clinical trials is critical to ensuring equitable and effective care for all individuals.
-
4 Things I’m Looking Forward To At SCOPE 2024
2/1/2024
The Summit for Clinical Ops Executives (SCOPE) begins Feb. 11. Discover four things Executive Editor Abby Proch is looking forward to at the annual event.
-
Digitizing The Clinical Protocol: Small Steps For Seismic Change
1/30/2024
A proliferation of clinical trial platform systems has meant increased friction for data exchange. Discover how TransCelerate is tackling this problem with small steps that yield big results.
-
Donating Surplus Clinical Trial Supplies Is Sustainability’s “Low-Hanging Fruit”
1/29/2024
ClinOps professionals know all too well the waste that occurs with leftover trial kits that are destroyed at the end of the trial. Explore donation as a way to give those kits a second life.
-
Ensuring Diversity And Accessibility In Neurological Research
1/26/2024
The landscape of neurological and rare disorders is as diverse as the human population it affects. Yet, clinical trials for these conditions have not always mirrored this diversity.
-
FDA Draft Guidance On “Rare Diseases: Considerations For The Development Of Drugs And Biological Products”
1/26/2024
Accenture Applied Life Science Solutions' Raj Bandaru, Ph.D. breaks down, summarizes, and shares detailed insight on the recent FDA Draft Guidance that addresses “Rare Diseases: Considerations for the Development of Drugs and Biological Products.”
-
3 Ways Biotechs Can Lower The Cost Of Clinical Trials
1/23/2024
LongeVC has identified three innovative models to help biotechs lower the cost of their clinical trials.
-
Objectively Evaluating Innovative Therapies And Making Sense Of Emerging Data
1/22/2024
Poseida Therapeutics' President and CEO, Kristin Yarema, Ph.D., details why allogenic CAR-T compares favorably with autologous CAR-T, and why, in many ways, allo has advantages that auto cannot hope to match.
-
Quick Tips And Hot Takes For Selecting Clinical Trial Technology
1/22/2024
Avoid inefficient decision-making that keeps key downstream activities in limbo and select a new clinical trial technology efficiently with this technology selection guide.